Coya Therapeutics, Inc. announced the appointment of Dr. Guillaume Dorothée, Ph.D., to Scientific Advisory Board 'SAB', joining a roster of scientific luminaries. Dr. Dorothée will provide insight and perspective into Coya's clinical programs in ALS and AD, and other indications that Coya is evaluating. Dr. Dorothée's seminal work has focused on the role of the immune system and peripheral-central immune crosstalk in the pathophysiology of AD and other neurodegenerative diseases, with a particular interest in neuroinflammation and its effects on beta Amyloid, Tau, and other AD pathology.

He has pioneered research into and how enhancing Tregs with low dose IL-2 plays a beneficial role in the pathophysiology of AD-like amyloid pathology while restoring cognitive function (Dansokho et al, Brain, 2016).